While symptom control is vital, 2026 has brought a renewed focus on Disease Modification through the expanded use of Besremi (ropeginterferon alfa-2b). Unlike older interferons that were plagued by harsh side effects, this long-acting version is proving in 2026 that it can induce deep molecular responses, potentially reducing the "JAK2 mutation burden" in the bone marrow. By targeting the...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
